A dedicated bipolar implantable cardioverter-defibrillator (ICD) lead for conduction system pacing (CSP) performed well in a first-in-human multicenter study. Placement of the novel UltiSynq CSP ICD ...
SAN FRANCISCO — An implantable cardioverter defibrillator (ICD) with a lead system that inserts just below the sternum performed promisingly in a recent early experience that sets the stage for a more ...
SAN FRANCISCO, CA—The subcutaneous implantable cardioverter-defibrillator (S-ICD; Boston Scientific) prevents most of the major lead-related complications seen with a transvenous system, the ATLAS ...
According to Dr Gust H Bardy (Seattle Institute for Cardiac Research, WA), if the device (S-ICD®, Cameron Health) becomes broadly available, it could potentially help avoid some of the disadvantages ...
NATICK, Mass., /PRNewswire/ -- Boston Scientific Corporation has conducted the first implant in the clinical trial of the next generation ACUITY™ X4 left-ventricular (LV) pacing leads and RELIANCE™ ...
SAN CLEMENTE, Calif.--(BUSINESS WIRE)--AtaCor Medical, Inc. has announced completion of its second human clinical study of the Extravascular Implantable Cardioverter Defibrillator (EV-ICD) Lead System ...
Please provide your email address to receive an email when new articles are posted on . Among patients who received implantable cardioverter defibrillator therapy, a subcutaneous vs. transvenous ...
Editor’s Note: The following guest post is published with the permission of its author, Edward J. Schloss, MD, (Twitter ID @EJSMD) the medical director of cardiac electrophysiology at Christ Hospital ...
Please provide your email address to receive an email when new articles are posted on . Transvenous ICD leads are associated with tricuspid regurgitation compared with subcutaneous ICDs. More research ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results